Patents by Inventor Anna M. Wu

Anna M. Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200165351
    Abstract: This invention relates to inhibition of the N-cadherin signaling using a humanized anti-N-cadherin antibody. In one embodiment, the invention relates to methods of treating an N-cadherin-mediated disease or N-cadherin-mediated disorder in a subject by contacting the subject with an anti-N-cadherin antibody.
    Type: Application
    Filed: June 6, 2018
    Publication date: May 28, 2020
    Inventors: Kirstin A. Zettlitz, Anna M. Wu, Robert E. Reiter
  • Patent number: 10407503
    Abstract: Human antibody fragments against c-Met have been identified through phage display technology. The high affinity and low immunogenicity make them very useful for both in vivo and in vitro applications. These novel human antibodies can greatly help the study of drug resistance in EGFR targeted therapies, and improve the diagnosis and treatment of cancer patients.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: September 10, 2019
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. Wu, Keyu Li
  • Publication number: 20180155449
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable ? carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Application
    Filed: September 18, 2017
    Publication date: June 7, 2018
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9765155
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: July 20, 2012
    Date of Patent: September 19, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9701754
    Abstract: The present invention provides recombinant antibody fragments which include a variable domain which has been modified by the addition of a tail sequence to its C-terminal end. The tail sequence comprises a terminal cysteine residue and an amino acid spacer and does not substantially affect the fragment's target-binding affinity. The present invention also provides pharmaceutical compositions comprising the described antibody fragments and a pharmaceutically acceptable carrier and methods of delivering an agent to cells of interest in a subject using the fragments as delivery vehicles. The invention further provides compositions comprising the described antibody fragments for the in vitro detection and measurement of target molecules which bind to the fragments and method of determining the presence or amount of such targets in a biological sample by contacting the sample with such compositions.
    Type: Grant
    Filed: May 27, 2010
    Date of Patent: July 11, 2017
    Assignee: City of Hope
    Inventors: Anna M. Wu, John E. Shively, Andrew A. Raubitschek, Mark A. Sherman, Tove Olafsen
  • Patent number: 9624304
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Grant
    Filed: March 23, 2015
    Date of Patent: April 18, 2017
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
  • Patent number: 9527919
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 27, 2016
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Publication number: 20160083450
    Abstract: This invention provides constructs comprising a protein scaffold, wherein the scaffold comprises Domain III, Domain IIIa, or Domain IIIb of human serum albumin or a polypeptide having substantial sequence identity to the Domain III, the Domain IIIa, or the Domain IIIb; and a targeting moiety in covalent linkage to the protein scaffold; and a therapeutic moiety and/or an imaging moiety in covalent linkage to the protein scaffold. The scaffold can be modified to tune the serum pharmacokinetics of the construct. In addition to methods of making the constructs, therapeutic, imaging and diagnostic uses of the constructs are also provided.
    Type: Application
    Filed: February 5, 2015
    Publication date: March 24, 2016
    Inventors: Anna M. WU, Vania E. Kenanova, Tove Olafsen
  • Publication number: 20150329641
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Application
    Filed: March 23, 2015
    Publication date: November 19, 2015
    Inventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
  • Publication number: 20150299326
    Abstract: Human antibody fragments against c-Met have been identified through phage display technology. The high affinity and low immunogenicity make them very useful for both in vivo and in vitro applications. These novel human antibodies can greatly help the study of drug resistance in EGFR targeted therapies, and improve the diagnosis and treatment of cancer patients.
    Type: Application
    Filed: December 2, 2013
    Publication date: October 22, 2015
    Inventors: Anna M. WU, Keyu LI
  • Publication number: 20150239983
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The Present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Application
    Filed: December 5, 2014
    Publication date: August 27, 2015
    Inventors: Anna M. WU, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Publication number: 20150191543
    Abstract: Disclosed herein, the parental antibodies from the hybridomas YTS 169.4.2.1 (YTS169) and 2.43 were engineered into minibody and diabody fragments. Both the YTS and 2.43 antibodies bind mCD8+. However, they differ in that the YTS 169 antibodies bind both Lyt2.1 and Lyt2.2 while the 2.43 antibodies bind an epitope that is Lyt2.2 specific. These novel minibodies and diabodies retained their antigen specificity as shown by flow cytometry and ImmunoPET imaging. Most importantly, both the 2.43 and YTS169 minibodies and diabodies produced high contrast ImmunoPET images of CD8+ lymphoid organs at only four hours post-injection.
    Type: Application
    Filed: August 6, 2013
    Publication date: July 9, 2015
    Inventors: Anna M. Wu, Richard Tavaré, Tove Olafsen
  • Patent number: 9011857
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: April 21, 2015
    Assignee: The Regents of The University of California
    Inventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki, Madhuri Wadehra, Kathy A. Kelly, Anna M. Wu
  • Publication number: 20150044694
    Abstract: Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue.
    Type: Application
    Filed: August 11, 2014
    Publication date: February 12, 2015
    Inventors: Anna M. WU, Shimon Weiss, Tove Olafsen, Fabien Florent Pinaud, Bhaswati Barat
  • Patent number: 8940298
    Abstract: The present invention provides novel high affinity antibodies and fragments thereof that bind to the cancer antigen PSCA. The antibodies of the present invention may be used for cancer diagnosis, prognosis, treatment, visualization, and the like. The present invention also provides methods for the detection, visualization, and treatment of various cancers expressing PSCA.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter, Eric J. Lepin, James D. Marks, Yu Zhou
  • Patent number: 8940871
    Abstract: The invention provides novel humanized antibody fragments that specifically bind prostate cell-surface antigen (PSCA), a protein which is overexpressed in variety of cancers, including prostate, bladder, and pancreatic cancer. Methods are provided for the use of the compositions of the invention for the treatment of cancer, diagnosis of cancer, to provide a prognosis of cancer progression, and for cancer imaging.
    Type: Grant
    Filed: March 20, 2007
    Date of Patent: January 27, 2015
    Assignee: The Regents of the University of California
    Inventors: Anna M. Wu, Robert E. Reiter
  • Patent number: 8785602
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Grant
    Filed: October 28, 2013
    Date of Patent: July 22, 2014
    Assignee: The Regents of the University of California
    Inventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
  • Patent number: 8779104
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Grant
    Filed: August 21, 2013
    Date of Patent: July 15, 2014
    Assignee: The Regents of the University of California
    Inventors: Jonathan Braun, Lynn K. Gordon, Kaori Shimazaki Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu
  • Patent number: 8703920
    Abstract: The present application provides fully human antibodies against N-Cadherin for therapeutic and diagnostic methods in cancer.
    Type: Grant
    Filed: November 9, 2009
    Date of Patent: April 22, 2014
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Eric Lepin, Anna M. Wu
  • Publication number: 20140072569
    Abstract: The present invention provides methods and compositions useful in the treatment or prevention of Chlamydia infections and cancer. The methods and compositions inhibit the entry of Chlamydia into a host cell expressing EMP2 by interfering with the interaction between the Chlamydia and EMP2. The methods and compositions target cancers which express or overexpress EMP2 nucleic acids and polypeptides by targeting EMP2.
    Type: Application
    Filed: October 28, 2013
    Publication date: March 13, 2014
    Applicant: The Regents of The University of California
    Inventors: Jonathan BRAUN, Lynn K. Gordon, Kaori Dadgostar, Madhuri Wadehra, Kathleen A. Kelly, Anna M. Wu